Want to see SE:QLINEA full AI Analyst Report?
QLINEA Stock Chart & Stats
kr29.00
>-kr0.01(-3.85%)
At close: 4:00 PM EST
kr29.00
>-kr0.01(-3.85%)
Day’s Range― - ―
52-Week Rangekr14.55 - kr74.06
Previous CloseN/A
Volume6.05M
Average Volume (3M)13.43K
Market Cap
kr313.76M
Enterprise Value-kr97.88M
Total Cash (Recent Filing)kr223.91M
Total Debt (Recent Filing)kr4.15M
Price to Earnings (P/E)―
Beta2.63
Next Earnings
Jul 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.75
Shares Outstanding18,949,081
10 Day Avg. Volume10,725
30 Day Avg. Volume13,430
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.49
Price to Sales (P/S)14.97
P/FCF Ratio-0.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.51
Revenue Forecast (FY)kr76.80M
Bulls Say, Bears Say
Bulls Say
Razor-and-blades Recurring ModelQ-linea’s instrument-plus-consumables model creates a structural recurring-revenue stream: instruments place the platform, consumables drive repeat sales and margin over time. As the installed base grows, consumable volumes scale predictably, supporting sustainable revenue and stronger long-term cash conversion than one-off sales alone.
Low Leverage And Equity RecoveryA light debt load and restored positive equity materially reduce solvency risk and give management financing flexibility for R&D, regulatory work, and commercial rollouts. This balance-sheet strength supports ongoing product commercialization without immediate refinancing pressure, a durable advantage during scale-up phases.
Focus On Sepsis And AST DiagnosticsTargeting sepsis and AST aligns with durable clinical priorities: hospitals require faster pathogen ID and susceptibility data to guide therapy. Structural demand for rapid diagnostics gives Q-linea a persistent addressable market and the potential for steady consumable usage as clinical adoption expands across microbiology labs.
Bears Say
Very High Cash BurnSustained, large negative operating and free cash flow relative to a small revenue base creates a structural financing requirement. Persistent cash burn forces reliance on external capital, risks dilution, and constrains investments in commercialization and scale-up absent a clear, near-term revenue inflection.
Small, Declining Revenue BaseA tiny and shrinking top line limits ability to absorb fixed costs and achieve operating leverage. Low instrument placements or consumable uptake suggests commercial traction is insufficient, prolonging the path to profitable scale and making margins and cash generation vulnerable until adoption meaningfully increases.
Deeply Negative Profitability And ReturnsLarge net losses and negative ROE indicate the company is destroying equity while scaling. Persistent negative margins reduce reinvestable cash and raise investor scrutiny on capital allocation. Without structural improvement in margins or revenue scale, profitability metrics are unlikely to normalize in the near term.
Q-linea AB News
QLINEA FAQ
What was Q-linea AB’s price range in the past 12 months?
Q-linea AB lowest stock price was kr14.55 and its highest was kr74.06 in the past 12 months.
What is Q-linea AB’s market cap?
Q-linea AB’s market cap is kr313.76M.
When is Q-linea AB’s upcoming earnings report date?
Q-linea AB’s upcoming earnings report date is Jul 10, 2026 which is in 6 days.
How were Q-linea AB’s earnings last quarter?
Q-linea AB released its earnings results on Apr 30, 2026. The company reported -kr1.772 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.772.
Is Q-linea AB overvalued?
According to Wall Street analysts Q-linea AB’s price is currently Overvalued.
Does Q-linea AB pay dividends?
Q-linea AB does not currently pay dividends.
What is Q-linea AB’s EPS estimate?
Q-linea AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Q-linea AB have?
Q-linea AB has 18,949,081 shares outstanding.
What happened to Q-linea AB’s price movement after its last earnings report?
Q-linea AB reported an EPS of -kr1.772 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.371%.
Which hedge fund is a major shareholder of Q-linea AB?
Currently, no hedge funds are holding shares in SE:QLINEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Q-linea AB
Q-linea AB (publ), founded in 2008 and based in Uppsala, Sweden, specializes in developing diagnostic instruments and associated consumables for infection detection. The company crafts advanced in vitro diagnostic platforms, specifically engineered to identify infectious diseases. A key product is ASTar, an innovative system designed to rapidly assess antibiotic susceptibility in positive blood cultures. Q-linea's overarching mission is to deliver cutting-edge solutions to healthcare professionals.
Technical Analysis
Vicore Pharma Holding AB
―
Isofol Medical AB
―
Biovica International AB Class B
―
Doxa AB
―
Guard Therapeutics International AB
―